Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:09:04 2024-04-30 EDT			5-day change	1st Jan Change
111.1 ^USD	-0.49%		+3.24%	+12.01%

07:41am	Wall Street: buoyed by Tesla, confident ahead of FOMC meeting	CF
04-29	Wall Street: buoyed by Tesla, confident ahead of FOMC meeting	CF

MODERNA : Barclays gives a Buy rating

May 07, 2021 at 06:16 am

In a research note published by Gena Wang, Barclays advises its customers to buy the stock. The target price is revised upwards from USD 194 to USD 178.

Latest news about Moderna, Inc.

Wall Street: buoyed by Tesla, confident ahead of FOMC meeting	01:41am	CF
Wall Street: buoyed by Tesla, confident ahead of FOMC meeting	04-29	CF
Moderna Signs Nonexclusive License Deal in Japan for COVID-19-related Intellectual Property	04-29	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	04-24	MT
Moderna to Collaborate With OpenAI to Launch New Generation of Medicines	04-24	MT
Moderna: strengthens collaboration with OpenAI	04-24	CF
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	04-24	DJ
Moderna, Inc. and OpenAI Collaborate to Advance mRNA Medicine	04-24	CI
Pfizer vs Moderna battle over COVID vaccine patents begins in UK	04-23	RE
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	04-22	RE
Moderna to deliver 12.5 million Covid vaccines to Brazil	04-22	CF
Sector Update: Health Care Stocks Advance Premarket Monday	04-22	MT
Moderna Secures Contract to Supply 12.5 Million COVID-19 Vaccine Doses to Brazil	04-22	MT
Moderna to Supply COVID-19 Vaccines to Brazil	04-22	MT
Moderna, Inc. Announces Contract with Ministry of Health in Brazil to Supply 12.5 Million Covid-19 Vaccines as Part of National Vaccination Campaign	04-22	CI
China's drugmakers can't sell mRNA shots but haven't quit yet	04-19	RE
Moderna Insider Sold Shares Worth $1,575,300, According to a Recent SEC Filing	04-16	MT
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...	04-15
Market outlook is uncertain, but optimism prevails	04-15
Redburn Adjusts Moderna's Price Target to $117 From $110	04-12	MT
Moderna pauses Kenya plant plans as COVID vaccine demand wanes	04-11	RE
Moderna Pausing Plan to Build Kenya Vaccine Production Plant	04-11	MT
Moderna Reportedly Pausing Plan to Build Kenya Vaccine Production Plant	04-11	MT
Moderna Reportedly Putting Plan for Kenya Vaccine Plant on Hold	04-11	MT
Moderna puts Kenya plant plans on hold as COVID vaccine demand slumps	04-11	RE

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 10:24 am

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 16, 2024 at 03:31 pm

More Strategies

Ratings for Moderna, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

111.6 USD

Average target price

134.3 USD

Spread / Average Target

+20.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+12.01%	42.74B
IQVIA HOLDINGS INC.	+1.58%	42.86B
LONZA GROUP AG	+45.09%	41.36B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.75%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.08%	18.63B
MEDPACE HOLDINGS, INC.	+29.97%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.98%	11.92B
UNITED THERAPEUTICS CORPORATION	+7.95%	11.21B
BIO-TECHNE CORPORATION	-16.19%	10.14B

Other Biotechnology & Medical Research

Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

MODERNA : Barclays gives a Buy rating

Latest news about Moderna, Inc.

Chart Moderna, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Moderna, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research